A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

NCT01171924 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Liver Cancer
Breast Cancer
Gastric Cancer
Non-Small Cell Lung Cancer

Interventions

DRUG: CUDC-101
DRUG: CUDC-101

Sponsor

Curis, Inc.